Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: A sub-analysis of the EASY trial

被引:10
|
作者
Bertrand, Olivier F. [1 ]
Rodes-Cabau, Josep [1 ]
Larose, Eric [1 ]
Nguyen, Can Manh [1 ]
Dery, Jean-Pierre [1 ]
Proulx, Guy [1 ]
Roy, Louis [1 ]
Poirier, Paul [1 ]
Costerousse, Olivier [1 ]
De Larochelliere, Robert [1 ]
机构
[1] Univ Laval, Hop Laval, Inst Univ Cardiol & Pneumol, Intervent Cardiol Labs, Ste Foy, PQ G1V 4G5, Canada
关键词
Abciximab; Intracoronary; Stent; Platelets; Transradial; ACUTE MYOCARDIAL-INFARCTION; PLATELET-RICH CLOTS; UNSTABLE ANGINA; ANGIOPLASTY; BOLUS; EPTIFIBATIDE; INFUSION; PCI;
D O I
10.1016/j.ijcard.2008.04.073
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In the EASY trial, we have shown the clinical equivalence between abciximab bolus-only and abciximab bolus followed by 12-h infusion in a wide spectrum of patients after percutaneous coronary intervention (PCI). Some reports have suggested better outcomes following intracoronary (IC) abciximab administration compared to intravenous (IV) delivery. We sought to compare cardiac biomarkers release and early and late clinical outcomes after IC or IV abciximab bolus delivery. Methods: From 1005 patients randomized in the EASY trial and undergoing transradial coronary stent implantation, 208 received IC abciximab bolus and 797 received IV abciximab bolus. Route of administration was left to operators' discretion. Creatine Kinase-MB, and Troponin-T (Tn-T) were obtained immediately prior to angiography, 4-6 h after PCI and the next day. MACE (death, MI, TVR) rate was evaluated at 30 days, 6 months and 12 months. Results: There were more patients with acute coronary syndrome (75% vs 64%, P=0.004) and previous MI (53% vs 42%, P=0.005) in the IC group and more patients with >= 3 dilated sites in the IV group (2% IC vs 7% IV, P=0.03). After PCI, the extent of Tn-T and CK-MB release remained comparable in both groups. The MACE rate was 2% in both groups at 30 days, 9% in IC bolus vs 5% in IV bolus (P=0.04) at 6 months and 10% in IC bolus vs 9% in IV bolus (P=0.50) at 12 months. By multivariate analysis, IC abciximab bolus was not associated with better outcomes at 12 months compared to IV bolus (HR 1.07, 95% CI 0.82-1.35, P=0.62). Conclusion: Compared to IV abciximab administration, IC abciximab was not associated with less cardiac biomarkers release or better clinical outcomes after uncomplicated transradial PCI. Further studies are required in clinical scenarios including patients with higher thrombotic burden and/or occluded vessels as in primary and rescue PCI. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:165 / 170
页数:6
相关论文
共 50 条
  • [21] Impact of abciximab on prognosis in diabetic patients undergoing primary percutaneous coronary intervention
    Perkan, Andrea
    Vitrella, Giancarlo
    Barbati, Giulia
    De Monte, Ariella
    D'Agata, Bianca
    Merlo, Marco
    Giannini, Francesco
    Della Grazia, Erica
    Rakar, Serena
    Salvi, Alessandro
    Igidbashian, Diran
    Morgera, Tullio
    Zalukar, Walter
    Sinagra, Gianfranco
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2013, 14 (02) : 127 - 135
  • [22] Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration
    Gu, Youlan L.
    Fokkema, Marieke L.
    Kampinga, Marthe A.
    de Smet, Bart J. G. L.
    Tan, Eng S.
    van den Heuvel, Ad F. M.
    Zijlstra, Felix
    TRIALS, 2009, 10 : 90
  • [23] Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration
    Youlan L Gu
    Marieke L Fokkema
    Marthe A Kampinga
    Bart JGL de Smet
    Eng S Tan
    Ad FM van den Heuvel
    Felix Zijlstra
    Trials, 10
  • [24] Intracoronary Compared to Intravenous Abciximab in Patients with ST Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention Reduces Mortality, Target Vessel Revascularization and Reinfarction after 1 Year
    Iversen, Allan Zeeberg
    Galatius, Soeren
    Abildgaard, Ulrik
    Galloe, Anders
    Hansen, Peter Riis
    Pedersen, Sune
    Engstroem, Thomas
    Jensen, Jan Skov
    CARDIOLOGY, 2011, 120 (01) : 43 - 49
  • [25] Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention
    Erdim, Refik
    Erciyes, Demet
    Gormez, Selcuk
    Karabay, Kanber Oecal
    Catakoglu, Alp Burak
    Aytekin, Vedat
    Demiroglu, Cemsid
    Gulbaran, Murat
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2010, 10 (04) : 340 - 345
  • [26] Intracoronary Compared With Intravenous Bolus Abciximab Application During Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction
    Eitel, Ingo
    Woehrle, Jochen
    Suenkel, Henning
    Meissner, Josephine
    Kerber, Sebastian
    Lauer, Bernward
    Pauschinger, Matthias
    Birkemeyer, Ralf
    Axthelm, Christoph
    Zimmermann, Rainer
    Neuhaus, Petra
    Brosteanu, Oana
    de Waha, Suzanne
    Desch, Steffen
    Gutberlet, Matthias
    Schuler, Gerhard
    Thiele, Holger
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (13) : 1447 - 1454
  • [27] Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: Design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial
    Thiele, Holger
    Woehrle, Jochen
    Neuhaus, Petra
    Brosteanu, Oana
    Sick, Peter
    Prondzinsky, Roland
    Birkemeyer, Ralf
    Wiemer, Marcus
    Kerber, Sebastian
    Schuehlen, Helmut
    Kleinertz, Klaus
    Axthelm, Christoph
    Zimmermann, Rainer
    Rittger, Harald
    Braun-Dullaeus, Ruediger C.
    Lauer, Bernward
    Burckhardt, Wolfgang
    Ferrari, Markus
    Bergmann, Martin W.
    Hambrecht, Rainer
    Schuler, Gerhard
    AMERICAN HEART JOURNAL, 2010, 159 (04) : 547 - 554
  • [28] Impact of Intracoronary Adenosine on Myonecrosis in Patients with Unstable Angina Pectoris Undergoing Percutaneous Coronary Intervention
    Kizilirmak, Filiz
    Gunes, Haci Murat
    Demir, Gultekin Gunhan
    Gokdeniz, Tayyar
    Guler, Ekrem
    Cakal, Beytullah
    Omaygenc, Mehmet Onur
    Yilmaz, Fatih
    Savur, Umeyir
    Barutcu, Irfan
    CARDIOVASCULAR DRUGS AND THERAPY, 2015, 29 (06) : 519 - 526
  • [29] Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: A meta-analysis of 8 randomized trials
    De Luca, Giuseppe
    Verdoia, Monica
    Suryapranata, Harry
    ATHEROSCLEROSIS, 2012, 222 (02) : 426 - 433
  • [30] Appropriate bolus administration of glycoprotein IIb/IIIa inhibitors for patients with acute coronary syndromes undergoing percutaneous coronary intervention: intracoronary or intravenous? A comprehensive and updated meta-analysis and systematic review
    Ali-Hassan-Sayegh, Sadegh
    Mirhosseini, Seyed Jalil
    Shahidzadeh, Arezoo
    Rahimizadeh, Elham
    Sarrafan-Chaharsoughi, Zahra
    Ghodratipour, Zahra
    Lotfaliani, Mohammad
    Rezaeisadrabadi, Mohammad
    Dehghan, Hamid Reza
    Bireta, Christian
    Weymann, Alexander
    Sabashnikov, Anton
    Popov, Aron-Frederik
    KARDIOLOGIA POLSKA, 2016, 74 (02) : 104 - 118